Douglas Thomas Fearon - Toxicology

Author Information

Douglas Thomas Fearon is a distinguished researcher affiliated with Cold Spring Harbor Laboratory in Cold Spring Harbor, NY, USA. His research primarily focuses on the complex interactions between cancer cells and the immune system, seeking to understand mechanisms of immune evasion and resistance to immunotherapy.

Research Contributions

Douglas Thomas Fearon has made significant contributions to the field of cancer biology and immunotherapy. His research includes the study of how carcinomas create a CXCL12-keratin-19 coating to evade T cell-mediated immune attacks, as well as the role of stromal fibroblasts in enhancing immune response. Notably, his work on CXCR4 inhibition has provided insights into inducing integrated immune responses in pancreatic and colorectal cancers. Additionally, he has explored the role of autophagy in promoting immune evasion in pancreatic cancer by degrading MHC-I.

Aliases

Douglas Thomas Fearon is also known by several aliases including Douglast . Fearon, Douglas Fearon, Doug T Fearon, Douglas T. Fearon, D T Fearon, D. T. Fearon, D.t. Fearon, and D. Fearon.

Publication and Citation Metrics

Citation Count	35,386
H-index	84
Paper Count	294

Publications:

Carcinomas assemble a filamentous CXCL12–keratin-19 coating that suppresses T cell–mediated immune attack

DOI: 10.1073/pnas.2119463119

Year: 2022

T cell-mediated development of stromal fibroblasts with an immune-enhancing chemokine profile

DOI: 10.1101/2022.04.03.486884

Year: 2022

AMD3100/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells.

DOI: 10.1038/s41416-021-01315-y

Year: 2021

Cancer cell CCR2 orchestrates suppression of the adaptive immune response

DOI: 10.1084/jem.20181551

Year: 2020

CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response

DOI: 10.1073/pnas.2013644117

Year: 2020

Abstract IA-04: Pancreatic cancer cells assemble a CXCL12-keratin 19 coating to resist immunotherapy

DOI: 10.1158/1538-7445.panca20-ia-04

Year: 2020

Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I

DOI: 10.1038/s41586-020-2229-5

Year: 2020

A framework for advancing our understanding of cancer-associated fibroblasts

DOI: 10.1038/s41568-019-0238-1

Year: 2020

Transglutaminase-2 of pancreatic cancer cells assembles a CXCL12-keratin 19-coat that mediates the resistance to immunotherapy

DOI: 10.1101/776419

Year: 2019

Distinct fibroblast subsets drive inflammation and damage in arthritis

DOI: 10.1038/s41586-019-1263-7

Year: 2019